Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

GT-015 endowed with both neuroprotective and cognition-enhancing properties

June 14, 2000

Centaur describes new nitrone with potential in MS at Immunology 2000

June 13, 2000

Cortex receives funding to test CX-516 in patients with mild cognitive impairment

June 9, 2000

More effective, better tolerated combinations for migraine

June 9, 2000

Rizatriptan + rofecoxib claimed by Merck for use in migraine

June 9, 2000

New mGluR1 antagonists claimed by Lilly for migraine and CNS disorders

June 9, 2000

New compounds for schizophrenia emerge from R&D at SmithKline Beecham

June 8, 2000

Down's syndrome research expedited by decoding of human chromosome 21

June 8, 2000

Provigil authorized for marketing in Italy for the treatment of narcolepsy

June 8, 2000

Teva's Copaxone recommended for approval in U.K.

June 8, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...